BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 36514072)

  • 1. Kinin B1 receptor blockade attenuates hepatic fibrosis and portal hypertension in chronic liver diseases in mice.
    Rampa DR; Feng H; Allur-Subramaniyan S; Shim K; Pekcec A; Lee D; Doods H; Wu D
    J Transl Med; 2022 Dec; 20(1):590. PubMed ID: 36514072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Igf2bp2 knockdown improves CCl
    Xu Z; He B; Jiang Y; Zhang M; Tian Y; Zhou N; Zhou Y; Chen M; Tang M; Gao J; Peng F
    Int Immunopharmacol; 2022 Sep; 110():108987. PubMed ID: 35820364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AMPK agonist AICAR ameliorates portal hypertension and liver cirrhosis via NO pathway in the BDL rat model.
    Hu L; Su L; Dong Z; Wu Y; Lv Y; George J; Wang J
    J Mol Med (Berl); 2019 Mar; 97(3):423-434. PubMed ID: 30721324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physalin D attenuates hepatic stellate cell activation and liver fibrosis by blocking TGF-β/Smad and YAP signaling.
    Xiang D; Zou J; Zhu X; Chen X; Luo J; Kong L; Zhang H
    Phytomedicine; 2020 Nov; 78():153294. PubMed ID: 32771890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of PDGF, TGF-β, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib.
    Liu Y; Wang Z; Kwong SQ; Lui ELH; Friedman SL; Li FR; Lam RWC; Zhang GC; Zhang H; Ye T
    J Hepatol; 2011 Sep; 55(3):612-625. PubMed ID: 21251937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis.
    Klein S; Rick J; Lehmann J; Schierwagen R; Schierwagen IG; Verbeke L; Hittatiya K; Uschner FE; Manekeller S; Strassburg CP; Wagner KU; Sayeski PP; Wolf D; Laleman W; Sauerbruch T; Trebicka J
    Gut; 2017 Jan; 66(1):145-155. PubMed ID: 26385087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quercetin prevents hepatic fibrosis by inhibiting hepatic stellate cell activation and reducing autophagy via the TGF-β1/Smads and PI3K/Akt pathways.
    Wu L; Zhang Q; Mo W; Feng J; Li S; Li J; Liu T; Xu S; Wang W; Lu X; Yu Q; Chen K; Xia Y; Lu J; Xu L; Zhou Y; Fan X; Guo C
    Sci Rep; 2017 Aug; 7(1):9289. PubMed ID: 28839277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human antigen R contributes to hepatic stellate cell activation and liver fibrosis.
    Woodhoo A; Iruarrizaga-Lejarreta M; Beraza N; García-Rodríguez JL; Embade N; Fernández-Ramos D; Martínez-López N; Gutiérrez-De Juan V; Arteta B; Caballeria J; Lu SC; Mato JM; Varela-Rey M; Martínez-Chantar ML
    Hepatology; 2012 Nov; 56(5):1870-82. PubMed ID: 22576182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Yu Gan Long Ameliorates Hepatic Fibrosis by Inhibiting PI3K/AKT, Ras/ERK and JAK1/STAT3 Signaling Pathways in CCl
    Li HG; You PT; Xia Y; Cai Y; Tu YJ; Wang MH; Song WC; Quan TM; Ren HY; Liu YW; Dan HX; Xu SQ
    Curr Med Sci; 2020 Jun; 40(3):539-547. PubMed ID: 32681257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapamycin ameliorates inflammation and fibrosis in the early phase of cirrhotic portal hypertension in rats through inhibition of mTORC1 but not mTORC2.
    Wang W; Yan J; Wang H; Shi M; Zhang M; Yang W; Peng C; Li H
    PLoS One; 2014; 9(1):e83908. PubMed ID: 24404143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hic-5 deficiency attenuates the activation of hepatic stellate cells and liver fibrosis through upregulation of Smad7 in mice.
    Lei XF; Fu W; Kim-Kaneyama JR; Omoto T; Miyazaki T; Li B; Miyazaki A
    J Hepatol; 2016 Jan; 64(1):110-7. PubMed ID: 26334580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective effect of Idelalisib on carbon tetrachloride-induced liver fibrosis via microRNA-124-3P/phosphatidylinositol-3-hydroxykinase signalling pathway.
    Li X; Li H; Zhang S; Zhang R; Li J; Wei Y; Yang C; Zhang F; Zhou H
    J Cell Mol Med; 2021 Dec; 25(24):11185-11197. PubMed ID: 34747105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The mouse Anxa6/miR-9-5p/Anxa2 axis modulates TGF-β1-induced mouse hepatic stellate cell (mHSC) activation and CCl
    Liao J; Zhang Z; Yuan Q; Luo L; Hu X
    Toxicol Lett; 2022 Jun; 362():38-49. PubMed ID: 35483553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dihydroartemisinin counteracts fibrotic portal hypertension via farnesoid X receptor-dependent inhibition of hepatic stellate cell contraction.
    Xu W; Lu C; Zhang F; Shao J; Yao S; Zheng S
    FEBS J; 2017 Jan; 284(1):114-133. PubMed ID: 27896916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic stellate cell autophagy inhibits extracellular vesicle release to attenuate liver fibrosis.
    Gao J; Wei B; de Assuncao TM; Liu Z; Hu X; Ibrahim S; Cooper SA; Cao S; Shah VH; Kostallari E
    J Hepatol; 2020 Nov; 73(5):1144-1154. PubMed ID: 32389810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docosahexaenoic acid attenuates carbon tetrachloride-induced hepatic fibrosis in rats.
    He J; Bai K; Hong B; Zhang F; Zheng S
    Int Immunopharmacol; 2017 Dec; 53():56-62. PubMed ID: 29035816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The anti-fibrotic effects of epigallocatechin-3-gallate in bile duct-ligated cholestatic rats and human hepatic stellate LX-2 cells are mediated by the PI3K/Akt/Smad pathway.
    Yu DK; Zhang CX; Zhao SS; Zhang SH; Zhang H; Cai SY; Shao RG; He HW
    Acta Pharmacol Sin; 2015 Apr; 36(4):473-82. PubMed ID: 25832428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Milk Fat Globule-EGF Factor 8, Secreted by Mesenchymal Stem Cells, Protects Against Liver Fibrosis in Mice.
    An SY; Jang YJ; Lim HJ; Han J; Lee J; Lee G; Park JY; Park SY; Kim JH; Do BR; Han C; Park HK; Kim OH; Song MJ; Kim SJ; Kim JH
    Gastroenterology; 2017 Apr; 152(5):1174-1186. PubMed ID: 27956229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of miR-188-5p alleviates hepatic fibrosis by significantly reducing the activation and proliferation of HSCs through PTEN/PI3K/AKT pathway.
    Riaz F; Chen Q; Lu K; Osoro EK; Wu L; Feng L; Zhao R; Yang L; Zhou Y; He Y; Zhu L; Du X; Sadiq M; Yang X; Li D
    J Cell Mol Med; 2021 Apr; 25(8):4073-4087. PubMed ID: 33689215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Terutroban, a TP-receptor antagonist, reduces portal pressure in cirrhotic rats.
    Rosado E; Rodríguez-Vilarrupla A; Gracia-Sancho J; Tripathi D; García-Calderó H; Bosch J; García-Pagán JC
    Hepatology; 2013 Oct; 58(4):1424-35. PubMed ID: 23703868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.